Latest news with #CarlHansen
National Post
2 days ago
- Business
- National Post
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
Article content VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2025 and that dosing has begun in a Phase 1 clinical trial of ABCL635 for the potential treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. Article content 'In the second quarter we hit two critical milestones, receiving authorization to initiate Phase 1 studies for both ABCL635 and ABCL575. I am pleased to announce today that we have successfully begun dosing the first participants in the Phase 1 study of ABCL635. This is a landmark achievement for AbCellera, one that completes our transition to a clinical-stage biotechnology company,' said Carl Hansen, Ph.D., founder and CEO of AbCellera. 'Today we also announced that a third program, ABCL688, has advanced into IND-enabling studies. With over $750 million in available liquidity, we are well-positioned to continue to execute our strategy.' Article content Q2 2025 Business Summary Article content Generated a net loss of $34.7 million, compared to a net loss of $36.9 million in 2024. Received authorization from Health Canada to initiate Phase 1 clinical trials for ABCL635 and ABCL575, bringing the cumulative total of molecules to reach the clinic to 18. Advanced ABCL688, an ion channel- or GPCR-targeted antibody development candidate (autoimmunity), into IND/CTA-enabling studies. Presented preclinical data for ABCL575 at the Society for Investigative Dermatology. Reached a cumulative total of 102 partner-initiated program starts with downstreams. Article content Recent Developments Article content ABCL635 (Endocrinology/Women's Health): AbCellera has initiated dosing of participants in a Phase 1 clinical trial of ABCL635, a potential non-hormonal, long-acting treatment for moderate-to-severe VMS, commonly known as hot flashes, associated with menopause. This is a randomized, placebo-controlled, double-blind Phase 1 study in healthy men and postmenopausal women with or without VMS. Its purpose is to evaluate safety, pharmacokinetics, pharmacodynamics, as well as frequency and severity of VMS with subcutaneous doses of ABCL635. The initial safety and efficacy data from this study is expected to be presented in mid 2026. ABCL575 (Immunology and Inflammation): AbCellera has initiated a Phase 1 clinical trial of ABCL575, which is being developed for the treatment of moderate-to-severe atopic dermatitis. This is a randomized, placebo-controlled, double-blind study to assess safety and tolerability in healthy participants following subcutaneous doses of ABCL575. ABCL575 is an OX40-ligand-targeting antibody engineered to support a dosing interval of once every 6 months. Article content AbCellera started discovery on an additional five partner-initiated programs with downstreams to reach a cumulative total of 102 partner-initiated program starts with downstreams in Q2 2025 (up from 93 on June 30, 2024). AbCellera and its partners have advanced a cumulative total of 18 molecules into the clinic (up from 14 on June 30, 2024). Article content Discussion of Q2 2025 Financial Results Article content Revenue – Total revenue was $17.1 million, compared to $7.3 million in Q2 2024. Research & Development (R&D) Expenses – R&D expenses were $39.2 million, compared to $40.9 million in Q2 2024. A greater proportion of R&D expenses are used on internal programs reflecting the increased emphasis on building the internal pipeline. Sales & Marketing (S&M) Expenses – S&M expenses were $3.0 million, compared to $3.1 million in Q2 2024. General & Administrative (G&A) Expenses – G&A expenses were $19.0 million, compared to $20.2 million in Q2 2024. Net Loss – Net loss of $34.7 million, or $(0.12) per share on a basic and diluted basis, compared to net loss of $36.9 million, or $(0.13) per share on a basic and diluted basis, in Q2 2024. Liquidity – $580 million of total cash, cash equivalents, and marketable securities and approximately $173 million in available non-dilutive government funding, bringing total available liquidity to approximately $753 million to execute on AbCellera's strategy. Article content Conference Call and Webcast Article content AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Article content The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call. Article content About AbCellera Biologics Inc Article content . Article content AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit Article content Definition of Key Business Metrics Article content We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. Article content Partner-initiated program starts with downstreams Article content represent the number of unique partner-initiated programs where we stand to participate financially in downstream success for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of the selection and initiation of projects by our partners and the resulting potential for near-term payments. Cumulatively, partner-initiated program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties (or royalty equivalents) in the mid- to long-term. Article content Molecules in the clinic Article content represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has reached 'open' status or has otherwise been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term. Article content AbCellera Forward-Looking Statements Article content This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Article content In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Article content Three months ended June 30, Six months ended June 30, 2024 2025 2024 2025 Revenue: Research fees $ 5,453 $ 6,639 $ 15,227 $ 10,707 Licensing revenue 370 10,445 550 10,613 Milestone payments 1,500 – 1,500 – Total revenue 7,323 17,084 17,277 21,320 Operating expenses: Research and development (1) 40,927 39,213 80,214 81,711 Sales and marketing (1) 3,136 3,009 6,501 5,851 General and administrative (1) 20,192 18,977 37,544 35,203 Depreciation, amortization, and impairment 36,522 5,470 41,366 10,801 Total operating expenses 100,777 66,669 165,625 133,566 Loss from operations (93,454 ) (49,585 ) (148,348 ) (112,246 ) Other (income) expense: Interest income (9,801 ) (7,592 ) (20,202 ) (15,643 ) Grants and incentives (3,310 ) (3,692 ) (6,585 ) (7,845 ) Other (32,156 ) (1,957 ) (30,627 ) 570 Total other income (45,267 ) (13,241 ) (57,414 ) (22,918 ) Net loss before income tax (48,187 ) (36,344 ) (90,934 ) (89,328 ) Income tax recovery (11,257 ) (1,617 ) (13,394 ) (8,980 ) Net loss $ (36,930 ) (34,727 ) $ (77,540 ) $ (80,348 ) Foreign currency translation adjustment (257 ) 4,341 (353 ) 1,721 Comprehensive loss $ (37,187 ) $ (30,386 ) $ (77,893 ) $ (78,627 ) Net loss per share Basic $ (0.13 ) $ (0.12 ) $ (0.26 ) $ (0.27 ) Diluted $ (0.13 ) $ (0.12 ) $ (0.26 ) $ (0.27 ) Weighted-average common shares outstanding Article content Article content Article content Article content Article content Contacts Article content Inquiries Article content Media: Tiffany Chiu; Article content media@ Article content , +1(236)521-6774 Article content Article content Partnering: Murray McCutcheon, Ph.D.; Article content Article content Article content
CNA
10-06-2025
- Entertainment
- CNA
Designer furniture for kids: 10 classic designs for your mini-me
Start your child's design education young with these miniature versions of design classics. The timeless design and quality of these pieces also fit seamlessly into any interior set up so parents need not compromise between classy aesthetics and fun furniture. As with any great design, get the originals. These were designed for utmost comfort, with reliable parts and friendly materials, which are important criteria as children use furniture in the most unpredictable ways. The children's versions have also been well researched to mimic the proportions and components of the adult seats that make them such beloved classics. 1. PAOLA LENTI CHILDREN'S COLLECTION Italian designer Paola Lenti founded her eponymous brand based on research that produced a high-tech synthetic yarn called Rope. It is 100 per cent recyclable, resistant to water, ultraviolet rays, mould and bacteria. It is also soft so it can be applied to both outdoor and indoor furniture. At this year's Milan Design Week, the brand unveiled a children's collection. Available in Paola Lenti's signature vibrant colours, it comprises miniature versions of the brand's most popular designs, including the Ami armchair with weaves of tubular fabric filled with soft material and the Orbitry swivel armchair made from Rope yarn. Available at Proof Living 2. WISHBONE CHAIR FROM CARL HANSEN & SON Carl Hansen & Son's Wishbone chair (also known as the CH24) is just about the most recognised – and copied – chair in the modern world. It was designed by Hans J Wegner, who was known as a virtuoso of chair design having designed over 500 in his lifetime. The chair was conceived in 1949 but has a timeless appeal due to its well-proportioned, sculptural form and fine craftsmanship. Comprising 14 solid oak components, it takes over 100 steps to hand-finish and assemble. Last year in celebration of the Danish designer's 110th birthday, Carl Hansen & Son released a children's version featuring the same signature solid oak Y-shaped back, curved frame and woven paper cord seat. Available from XTRA 3. MINI TOGO FROM LIGNE ROSET French furniture brand Ligne Roset's Togo is a well-known classic. Designer Michel Ducaroy got the idea for this low-slung sofa with a crumpled shape while brushing his teeth, when he noticed the scrunched shape of his half-used toothpaste tube. Launched in 1973, the sofa that sits directly on the floor without a base encapsulates the laid-back mood of the hippie era. Interest in the Togo has revived oft late, with the sofa being seen all over social media. Its casual and inviting character, and lack of sharp parts make it perfect for children. The mini version is available in more than 70 colours. 4. UP JUNIOR ARMCHAIR FROM B&B ITALIA Gaetano Pesce designed the Up 50 armchair in 1969 for Italian furniture manufacturer B&B Italia. Like the Togo, it was conceived in the bathroom. While showering, Pesce took note of how a sponge shrank when pressed and then returned to its original volume. He then created a seat that is compacted into a four-inch-thick disk and rises from the floor into an armchair when removed from its PVC envelope. The bulbous shape references the silhouettes of ancient fertility goddesses. Affixed to a ball-like ottoman with a chain, it was Pesce's statement on the suffering of women caused by the 'prejudice of men'. On the other hand, its playful form is an instant hit with children and the junior version fits small children just right. 5. MINI TWISTY FROM HC28 COSMO HC28 Cosmo is a design brand founded in Beijing. It works with local and international designers to make modern furniture with good-quality materials and premium craftsmanship. Designed by Roderick Vos, the Twisty armchair was inspired by an AI-generated image, with round tubes twisted to form a complex loop where a depressed segment becomes the seat. The armchair's tubular components and lack of sharp corners mean it is safe for children. The Mini Twisty is is available in bright red and tangerine – perfect for a spot of colour in a child's bedroom. Available from Made & Make 6. ARMLESS CHAIR FROM NEXTMARUNI Hiroshima-based Japanese wood manufacturer Maruni started the Nextmaruni project in 2004 to create a collection of chairs designed by a group of Japanese and international designers. Pritzker Architecture Prize-winners Kazuyo Sejima and Ryue Nishizawa of Japanese design studio SANAA came up with the Armless chair, featuring an asymmetrical "bunny ears" back. The minimal design captures the essence of SANAA's ethos. In 2011, two smaller versions were released – the mini and minimini. They are available in eight colours, including a natural colour celebrating the beauty of beech wood. 7. ROULETTE OUTDOOR SEAT FROM VONDOM Renowned Finnish designer Eero Aarnio's works are found in the most prestigious museums, including the Victoria and Albert Museum in London and the Museum of Modern Art (MoMA) in New York. For Spanish outdoor furniture brand Vondom, he designed several pieces, including the Roulette rocking chair, which he conceived for both adults and children to enjoy. Aarnio wanted to create a plastic chair with the legs integrated into the body, as well as experiment with a rotation molding technique in chair design. Its name evokes the chair's spinning movement. Available from XTRA 8. SERIES 7 CHAIR FROM FRITZ HANSEN Danish designer Arne Jacobsen designed many chairs, including the Series 7 and Drop chairs for Fritz Hansen, which have become icons. They are also well made. For example, the Series 7 chair is made from nine layers of moulded veneer for strength, flexibility and durability despite its slim profile. The children's version is stackable for space saving. It is also available in a high-seat version called Series 7 Junior chair. Fritz Hansen also has its iconic Lily, Ant and Grand Prix chairs in children's sizes. Available from W Atelier 9. PANTON JUNIOR BY VITRA Danish designer Verner Panton was a prominent designer of the post-World War II era. One of his best-known designs was the Panton chair. It was the result of an experiment in making furniture with fibreglass-reinforced polymer that can be moulded into any shape and mass-produced, making it more affordable. Initially, no one wanted to make Panton's cantilevered design – he had gone to almost 20 companies before Swiss manufacturer Vitra took on the task in 1963. Today's version is made from a more flexible and durable polypropylene. The Panton Junior is approximately 25 per cent smaller than the full-sized version and can carry weight of up to 34kg. 10. BABY UTRECHT ARMCHAIR FROM CASSINA With its slanted base and blanket-stitched edges, Gerrit Thomas Rietveld's Utrecht armchair has become a recognisable classic. The Dutch architect and furniture designer created it in 1935 for the Metz&Co department store in Amsterdam. Named after his native city, it is a symbol of the Neoplastic (aka De Stijl) movement, which propagated primary colours and the elemental composition of simple, geometric shapes in right angles. Being entirely wrapped in fabric means it is comfortable and safe for young children to use. The Baby Utrecht is a re-proportioned version that comes in 20 shades.
Yahoo
09-06-2025
- Business
- Yahoo
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Investment Ides by Antonio's Substack. In this article, we will summarize the bulls' thesis on ABCL. AbCellera Biologics Inc. (ABCL)'s share was trading at $2.14 as of 2nd June. ABCL's trailing P/E was 19.92 according to Yahoo Finance. A biopharmaceutical facility with technicians working on a manufacturing line of treatments and preventions. Abcellera is approaching a potential inflection point as it advances two new molecules—ABCL575 and ABCL635—into clinical trials, signaling its progress from a platform with promise to one capable of solving real-world medical problems. ABCL575 targets the OX-40 pathway, a critical immune regulator, and is being trialed for atopic dermatitis, with broader implications for treating alopecia and other chronic conditions that often stem from underlying viral or bacterial infections. CEO Carl Hansen noted that the same mechanism might have therapeutic value across autoimmune disorders, cancers, and infectious diseases, making OX-40 a cornerstone of Abcellera's ambitions. Meanwhile, ABCL635 targets the NK3R receptor in the brain's infundibular nucleus, effectively regulating endocrine balance and alleviating menopausal hot flashes. Since NK3R is part of the expansive GPCR receptor family, success here could validate Abcellera's ability to target a vast range of physiological functions, from hormone control to mood and sensory regulation. Both candidates exemplify the same core strength of Abcellera's platform: designing molecules with highly specific shapes to achieve precise biological effects. This shape-function relationship underpins the company's long-term vision of building a foundational biotech platform capable of producing tailored therapeutics. Although Abcellera's current financials remain weak, reflecting high risk, clinical success would dramatically increase its operating leverage and establish its relevance across a wide therapeutic spectrum. The platform's success could mirror and complement businesses like Hims, where data on bodily processes meets Abcellera's molecular solutions. While early in its journey, Abcellera's emerging capabilities suggest transformative potential if early trials succeed. Previously, we have covered ABCL in January 2025 wherein we summarized a by Jack Prescott on Twitter. The author highlighted the company's differentiated antibody discovery platform, which used microfluidics and AI to support an asset-light, partnership-driven model with firms like Eli Lilly and Moderna. Despite setbacks post-COVID, AbCellera maintained strong financials with $700M in cash, minimal debt, and over 200 pipeline programs, while its new GMP facility and government support positioned it for future clinical and commercial growth. Unfortunately, his thesis did not play out and the stock is down 26% since our coverage. However, due to the company's recent advances in the clinical trial process of two new molecules, we are optimistic about Antonio's thesis. AbCellera Biologics Inc. (ABCL) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held ABCL at the end of the first quarter which was 20 in the previous quarter. While we acknowledge the potential of ABCL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
National Post
08-05-2025
- Business
- National Post
AbCellera Reports Q1 2025 Business Results
Article content VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. Article content Article content 'After completion of a successful first quarter, we are excited to introduce ABCL635 as a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes) associated with menopause. ABCL635 is positioned as a next-generation neurokinin 3 receptor (NK3R) antagonist with an improved safety profile and convenient dosing regimen. If successful, we believe it has the potential to be a highly differentiated product in a large and established market,' said Carl Hansen, Ph.D., founder and CEO of AbCellera. 'We ended the quarter with over $800 million in available liquidity to execute on our strategy and anticipate starting Phase 1 clinical trials for both ABCL635 and ABCL575 in the second half of 2025.' Article content Earned $4.2 million in total revenue. Generated a net loss of $45.6 million, compared to net loss of $40.6 million in 2024. Reached a cumulative total of 97 partner-initiated program starts with downstreams. Maintained a cumulative total of 16 molecules to have reached the clinic. Article content AbCellera started discovery on an additional partner-initiated program with downstreams to reach a cumulative total of 97 partner-initiated program starts with downstreams in Q1 2025 (up from 90 on March 31, 2024). AbCellera's partners have advanced a cumulative total of 16 molecules into the clinic (up from 13 on March 31, 2024). Article content Discussion of Q1 2025 Financial Results Article content Revenue – Total revenue was $4.2 million, compared to $10.0 million in Q1 2024. In both periods, the majority of revenues were research fees generated by our partnerships. Research & Development (R&D) Expenses – R&D expenses were $42.5 million, compared to $39.3 million in Q1 2024, reflecting growing investments in internal programs. Sales & Marketing (S&M) Expenses – S&M expenses were $2.8 million, compared to $3.4 million in Q1 2024. General & Administrative (G&A) Expenses – G&A expenses were $16.2 million, compared to $17.4 million in Q1 2024. Net Loss – Net loss of $45.6 million, or $(0.15) per share on a basic and diluted basis, compared to net loss of $40.6 million, or $(0.14) per share on a basic and diluted basis, in Q1 2024. Liquidity – $633 million of total cash, cash equivalents, and marketable securities and approximately $178 million in available non-dilutive government funding, bringing total available liquidity to approximately $810 million to execute on AbCellera's strategy. Article content AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Article content The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call. Article content About AbCellera Biologics Inc. Article content AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit Article content We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. Article content Partner-initiated program starts with downstreams represent the number of unique partner-initiated programs where we stand to participate financially in downstream success for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of the selection and initiation of projects by our partners and the resulting potential for near-term payments. Cumulatively, partner-initiated program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties (or royalty equivalents) in the mid- to long-term. Article content Molecules in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has reached 'open' status or has otherwise been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term. Article content AbCellera Forward-Looking Statements Article content This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Article content In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Article content Article content Article content Article content Article content Article content
Tatler Asia
02-05-2025
- Entertainment
- Tatler Asia
Home tour: A Parisian apartment blending 18th-century grandeur with curated antiques
Above The bright and cheerful apartment with pops of vibrancy and drama Above The 18th-century carved gilded mirror atop the fireplace Above The Venetian snake-design table and marble apple Although the property had undergone previous renovations, and Silvestry's design team was brought in to decorate the modernised space, they faced an extraordinarily tight timeline due to restrictions implemented in anticipation of the Olympic Games held in July of the previous year. 'Given the scale of the project, even minor delays could cause a ripple effect, so keeping everything on track required precise scheduling and constant communication,' divulges Silvestry, who was hired in April before receiving the keys in June on the day the purchase was finalised. Don't miss: 7 luxury boutique hotels in Paris for the stylish Olympics 2024 spectator Above The 18th-century Florentine painting from Yveline Antiques in the dining area Above The antique chandelier's delicate design plays off the glamorous architectural features Above First edition Wishbone chairs by Carl Hansen provides a contemporary respite She adds: 'While working within the constraints of available stock items, and facing delivery delays due to restricted access to the area caused by preparations for the Olympic Games, we took a proactive approach by maintaining flexibility in our design selections, ensuring that every design decision stayed true to our vision.' Read more: Home tour: A black-and-white home in Colmar inspired by the Eiffel Tower and Statue of Liberty Despite these challenges, Silvestry completed the project in just three weeks, delivering a bright and cheerful apartment with dramatic elements that exceeded the clients' expectations. 'The space is beautiful, and I love a good challenge,' she reflects. Above The blue-toned kitchen area with wooden herringbone-patterned flooring and white cabinetry Above Family-friendly surfaces with enhanced charm overtime while allowing carefree enjoyment Above Henry Walter Klein's midcentury teak chairs with reupholstered in bright blue fabric by Pierre Frey Based in Paris, the interior designer enjoys access to exquisite antique pieces from the Marché aux Puces and other specialty markets throughout the city. A serendipitous discovery of a stunning gold and green mirror and chandelier from Lila K Antiques inspired the apartment's design direction. 'The green was already within the apartment palette and the chandelier's delicate design was as glamorous as the architectural features,' Silvestry explains. See also: Inside Chee Soon & Fitzgerald: A little shop of treasures in Redfern, Sydney Above One of the bathrooms with fixtures reminiscent of the building's illustrious past Above Another bathroom is fitted with a more contemporary vanity and colour In the freshly repainted living room, the 18th-century carved gilded mirror now crowns the fireplace. Creating visual harmony, an 18th-century Florentine painting from Yveline Antiques depicting Adam receiving the forbidden fruit adorns the main wall. 'To add a sense of intrigue and humour, the painting was complemented with a pair of stunning Venetian snake-design tables and an 18th-century marble apple,' she reveals. Don't miss: Home tour: Inside Kai-yin Lo's Hong Kong home—a treasure trove of antiques and her prized jewellery design Above Refreshing hues of blue in the guest room with arched doorways Furthermore, for the dining area, Silvestry also managed to find first edition Wishbone chairs by Carl Hansen alongside a complementary 1960s Scandinavian-style table crafted in France. Meanwhile, Henry Walter Klein's midcentury teak chairs, reupholstered in Pierre Frey fabric, anchor the breakfast nook in the kitchen with its wooden herringbone flooring, lending character and authenticity to the classic design. Read more: 5 interior designer tips for kid-friendly bedrooms that grow with your children 'We also reupholstered some swivel chairs with Dedar fabric–both outdoor fabrics for long-lasting, heavy-duty use,' Silvestry notes. 'Considering their young children, we selected surfaces that develop a beautiful patina over time, enhancing the charm while allowing carefree enjoyment.' Above The primary suite through the ornate architrave and French doors Above The children's room adheres to the overall green colour palette 'My favourite aspect was having the opportunity to enhance the beautiful volumes and extraordinary Parisian space of the living room and kitchen,' the interior designer concludes. 'The lofty ceilings and intricate architectural details provided the perfect foundation for restoring some of the home's original grandeur through a refined yet unexpected interplay of textures–making this project one of my favourites.' NOW READ Step inside these 5 renovated Parisian homes with stunning interiors 7 iconic cantilever chairs that shaped modern furniture How 'interiors disruptor' Alex Alonso embraces colourful maximalism in summer homes Credits Photography: Benoît Linero
